secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2026-08-11T12:10:25+00:00
Accession:  0001104659-26-093782
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics Q2 2026: Cash $11.3M, VIRAGE2 first patients dosed
--------------------------------------------------------------------

- Cash and cash equivalents $11.3M as of June 30, 2026; runway into Q1 2027.
- G&A expenses down 82% YoY to $2.0M from $11.2M; prior-year $9.2M contingent consideration adjustment.
- R&D expenses down 35% to $1.3M from $2.0M; H1 2026 net loss $5.3M.
- First patients dosed in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment completion expected H2 2026.
- Proposed Phase 2/3 retinoblastoma trial design completed; FDA discussion planned Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/0001104659-26-093782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-093782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer